BRPI0720879A2 - microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo. - Google Patents

microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.

Info

Publication number
BRPI0720879A2
BRPI0720879A2 BRPI0720879A BRPI0720879A BRPI0720879A2 BR PI0720879 A2 BRPI0720879 A2 BR PI0720879A2 BR PI0720879 A BRPI0720879 A BR PI0720879A BR PI0720879 A BRPI0720879 A BR PI0720879A BR PI0720879 A2 BRPI0720879 A2 BR PI0720879A2
Authority
BR
Brazil
Prior art keywords
tissue factor
carrier
composition
manufacture
processes
Prior art date
Application number
BRPI0720879A
Other languages
English (en)
Inventor
Pedreño Egea Javier
Ramón Rodríguez Fernámdez-Alba Juan
Caveda Catasús Luis
Original Assignee
Thrombotargets Europe S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombotargets Europe S L filed Critical Thrombotargets Europe S L
Publication of BRPI0720879A2 publication Critical patent/BRPI0720879A2/pt
Publication of BRPI0720879B1 publication Critical patent/BRPI0720879B1/pt
Publication of BRPI0720879B8 publication Critical patent/BRPI0720879B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

microvesícula derivada de fermento carreador de fator de tecido(tf), composição e composição farmacêutica que a compreende e processos para a sua manufatura expõem-se microvesículas derivadas de fermento portadoras de fator de tecido que compreendem uma membrana de fermento e uma proteína de fator de tecido, ou um fragmento da mesma, ou uma proteína de fator de tecido ou um fragmento da mesma fundida a outro peptídeo como uma proteína de fusão tendo atividade prócoagulante. os ditos produtos podem ser usados como agentes pró-coagulantes no tratamento de hemorragias em um paciente.
BRPI0720879A 2006-12-29 2007-12-28 microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação BRPI0720879B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380342A EP1939218A1 (en) 2006-12-29 2006-12-29 Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
EP06380342.3 2006-12-29
PCT/EP2007/064644 WO2008080989A1 (en) 2006-12-29 2007-12-28 Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0720879A2 true BRPI0720879A2 (pt) 2018-12-26
BRPI0720879B1 BRPI0720879B1 (pt) 2020-11-24
BRPI0720879B8 BRPI0720879B8 (pt) 2021-05-25

Family

ID=38055194

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720879A BRPI0720879B8 (pt) 2006-12-29 2007-12-28 microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação

Country Status (13)

Country Link
US (1) US8759294B2 (pt)
EP (2) EP1939218A1 (pt)
JP (1) JP4813603B2 (pt)
CN (1) CN102007144B (pt)
AR (1) AR064720A1 (pt)
AU (1) AU2007341252B2 (pt)
BR (1) BRPI0720879B8 (pt)
CA (1) CA2673996C (pt)
ES (1) ES2394013T3 (pt)
MX (1) MX2009007085A (pt)
PL (1) PL2118134T3 (pt)
RU (1) RU2492184C2 (pt)
WO (1) WO2008080989A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130052647A1 (en) * 2010-02-10 2013-02-28 Marianna Goldrick Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery
EP2380905A1 (en) 2010-04-19 2011-10-26 Thrombotargets Europe, S.L. Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof
BR112013000024B1 (pt) 2010-07-01 2021-11-23 Aeon Medix Inc Composição para entregar um agente anticancer e método para preparação de microvesículas carregadas com um agente anticâncer, a partir de protoplastos de células bacterianas
JP2012168012A (ja) 2011-02-14 2012-09-06 Nippon Koden Corp 血管内皮障害を検査するための新規な検査方法および検査用キット
WO2013150142A1 (en) * 2012-04-05 2013-10-10 Ludwig-Maximilians-Universität München Method for the preparation of a strain- adapted vaccine
EP2745852A1 (en) 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Sealant compositions
EP2759305A1 (en) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Hemostatic compositions
WO2014159662A1 (en) 2013-03-13 2014-10-02 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
EP3008192B1 (en) 2013-06-11 2019-07-17 Takara Bio USA, Inc. Protein enriched microvesicles and methods of making and using the same
WO2017087897A1 (en) 2015-11-18 2017-05-26 Arytha Biosciences, Llc Processes and systems for preparing cellular or viral membranes and nanoparticles
CN106645665B (zh) * 2016-12-27 2019-02-26 北京赛科希德科技股份有限公司 一种凝血酶时间检测试剂
KR102015116B1 (ko) 2018-05-04 2019-10-21 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084251B1 (en) * 1987-02-12 2006-08-01 Genentech, Inc. Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
US6994988B1 (en) * 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DE69832628T2 (de) * 1997-04-23 2006-09-07 Instrumentation Laboratory S.P.A. Rekombinant-kaninchengewebefaktor basiertes prothrombinzeitreagenz
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
RU2002111683A (ru) 1999-10-01 2004-03-10 Тугаи Сейяку Кабусики Кайся (Jp) Профилактика и лечение заболеваний, связанных со свертыванием крови
DK1222854T3 (da) * 1999-10-01 2011-03-14 Chugai Pharmaceutical Co Ltd Forebyggelse og behandling af sygdomme forbundet med blodkoagulering
US6248353B1 (en) * 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
US20030166593A1 (en) 2001-04-30 2003-09-04 Kenneth Chien Non-viral vesicle vector for cardiac specific gene delivery
WO2002094016A1 (en) * 2001-05-18 2002-11-28 Chugai Seiyaku Kabushiki Kaisha Knockin nonhuman animal producing human tissue factor
CN101014711A (zh) * 2004-06-25 2007-08-08 阿尔特生物科学公司 植物中组织因数的制造

Also Published As

Publication number Publication date
RU2492184C2 (ru) 2013-09-10
MX2009007085A (es) 2009-07-09
RU2009129143A (ru) 2011-02-10
AU2007341252A1 (en) 2008-07-10
JP2010514433A (ja) 2010-05-06
US20100047335A1 (en) 2010-02-25
JP4813603B2 (ja) 2011-11-09
WO2008080989A1 (en) 2008-07-10
CN102007144A (zh) 2011-04-06
AU2007341252B2 (en) 2012-05-31
EP2118134A1 (en) 2009-11-18
CN102007144B (zh) 2014-06-04
BRPI0720879B1 (pt) 2020-11-24
PL2118134T3 (pl) 2013-02-28
CA2673996C (en) 2017-12-12
EP2118134B1 (en) 2012-08-29
EP1939218A1 (en) 2008-07-02
CA2673996A1 (en) 2008-07-10
AR064720A1 (es) 2009-04-22
ES2394013T3 (es) 2013-01-04
BRPI0720879B8 (pt) 2021-05-25
US8759294B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas
MY154826A (en) Fusion protein capable of binding vegf
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
FI4074331T3 (fi) Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
ECSP12012272A (es) Proteínas que se unen al tnf-?
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
BRPI1015424A2 (pt) métodos e composições utilizando peptídeos e proteínas com elementos de terminação c.
ECSP088463A (es) Antagonistas de activina-actriia y usos para promover el crecimiento óseo
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
ES2532985T3 (es) Proteínas quiméricas de toxoide de Shiga
BRPI0620125A8 (pt) método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra
CL2008003357A1 (es) Procedimiento para obtener una solucion de albumina humana con alta capacidad de union de moleculas que comprende una diafiltracion, estabilizacion con nacl y aminoacidos sin adicion de acidos grasos, pasteurizacion y una segunda diafiltracion.
Nicosia et al. Mimicking molecular pathways in the design of smart hydrogels for the design of vascularized engineered tissues
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
BR112013009660A8 (pt) Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein
BR112013022557A2 (pt) ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos
BR112017021016A2 (pt) preparação de proteína, composição farmacêutica, proteína de fusão, polinucleotídeo isolado, estrutura de ácido nucleico, método para tratamento de doença ou condição associada ao excesso de glutamato, e método de purificação de um polipeptídeo
ATE439443T1 (de) NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.